Pre-Open Movers 09/08: (ALBO) (NKLA) (SPRO) Higher; (CRBP) (ACMR) (TSLA) Lower (more...)
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 4/23/2024
- Stocks gear up for Big Tech earnings; yen toys with danger zone
- JPMorgan is worried about further S&P 500 sell-off potential
- Oil rises on robust EU data as Mideast tensions linger
- China acquired top-end Nvidia AI chips despite recent US ban- Reuters
- SAP Q1 results fall short of Wall Street estimates as transformation kicks off
- Fisker (FSR) Appoints Michael Healy as Chief Restructuring Officer
- Kroger (KR), Albertsons and C&S Wholesale Grocers Announce an Updated and Expanded Divestiture Plan
- Costar Group (CSGP) to Acquire Matterport (MTTR) for $5.50/sh Cash and Stock
- Jaguar Health (JAGX) Files $75M Mixed Shelf
- Apple (AAPL) PT Lowered to $210 at Morgan Stanley, 'We'd buy post-earnings weakness'
- After-hours movers: Cadence Design Systems, Cleveland-Cliffs, Riot Platforms, and more
- Midday movers: Tesla, Li Auto and CNH Industrial fall; Salesforce rises
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
Susquehanna Reiterates Positive Rating on Boeing (BA)
September 10, 2020 7:32 AM EDTSusquehanna analyst Charles Minervino reiterated a Positive rating and $210.00 price target on Boeing (NYSE: BA). While the 737 MAX recertification appears to be making progress, The end of 3Q is approaching without an approval. This, coupled with the COVID-related challenges and now 787 issues,... More
Albireo Pharma (ALBO) Prices 4M Share Common Offering at $40/Sh
September 10, 2020 5:48 AM EDTAlbireo Pharma Inc. (NASDAQ: ALBO) announced today the pricing of its previously announced underwritten public offering of 4,000,000 shares of its common stock at a price to the public of $40.00 per share. Albireos gross proceeds from this offering are expected to be $160 million, before deducting... More
Spero Therapeutics (SPRO) Announces Proposed 8M Share Common Offering
September 9, 2020 4:34 PM EDTSpero Therapeutics, Inc. (NASDAQ: SPRO) today announced that it has commenced an underwritten public offering of 8,000,000 shares of common stock in the aggregate, consisting of an offering of shares of common stock (the common stock offering) and shares of non-voting Series D Convertible Preferred Stock with each share of Series D Convertible Preferred Stock being convertible into 1,000 shares of common stock. All of the... More
Albireo Pharma (ALBO) PT Raised to $79 at Jefferies
September 8, 2020 1:32 PM EDTJefferies analyst Eun Yang raised the price target on Albireo Pharma (NASDAQ: ALBO) to $79.00 (from $50.00) while maintaining a Buy rating.
... MoreAlbireo Pharma (ALBO) PT Raised to $67 at H.C. Wainwright
September 8, 2020 12:22 PM EDTH.C. Wainwright analyst Ed Arce raised the price target on Albireo Pharma (NASDAQ: ALBO) to $67.00 (from $50.00) while maintaining a Buy rating.
The analyst commented, "This morning, Albireo announced positive topline results from the global, pivotal, Phase 3 PEDFIC 1 trial (NCT03566238) of lead drug, odevixibat (40 µg/kg/day or 120 µg/kg/day oral dose), for the treatment of children (aged 6 months to 16 years) with progressive familial intrahepatic cholestasis (including PFIC1 and non-truncated PFIC2). PEDFIC 1 met the difficult-to-achieve U.S. regulatory (FDA) primary efficacy endpoint of pruritus improvement (as measured by the PRUCISION 0-4 scale instrument)... More
